Michael Makris/LinkedIn
Jun 18, 2026, 06:43
Michael Makris: Will New Anti-TFPI Drug Armocibat Behaves any Different to Concizumab or Marstacimab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn:
“A Chinese company called Suzhou Alphamab is making an anti-TFPI drug called armocibat, for use in haemophilia with and without inhibitors.
The drug is in phase III at present.
They have just signed a license agreement for a Russian company called Nanolek to produce the drug.
I have no reason to believe that armocibat behaves any different to concizumab or marstacimab, but I hope they have safety surveillance systems to monitor for thrombosis when this drug is no longer in clinical trials.”
Stay updated with Hemostasis Today.
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation
-
Nov 17, 2026, 05:41Boitumelo Malatji: South African Delegation Advances Advocacy Strategies at NNHF Southern Africa Workshop
-
Nov 17, 2026, 05:36Joining the PACTA Uganda Mental Health and Addiction Community Camp 2026 – Tackle Sickle Cell Africa
-
Nov 17, 2026, 05:30Nathan Connell: Women’s Hematology Summit 2027 to Address Hematologic Health Across the Lifespan
-
Nov 17, 2026, 05:25Mane Kurghinyan: Representing Armenia and HemAI Dynamics at the Falling Walls Lab Global Finale 2026